Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lorraine Dalens"'
Autor:
Nicolas Roussot, Jean-David Fumet, Emeric Limagne, Marion Thibaudin, Alice Hervieu, Audrey Hennequin, Sylvie Zanetta, Lorraine Dalens, Théo Fourrier, Loick Galland, Pierre Jacob, Aurélie Bertaut, Emilie Rederstorff, Cédric Chevalier, Sarah Ghirardi, Elodie Gilbert, Azzat Khoukaz, Etienne Martin, Constance Nicolet, Magali Quivrin, David Thibouw, Noémie Vulquin, Gilles Truc, Magali Rouffiac, Francois Ghiringhelli, Céline Mirjolet
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-15 (2023)
Abstract Background Immunotherapy targeting the PD-1/PD-L1 pathway is a standard of care in a number of metastatic malignancies, but less than a fifth of patients are expected to respond to ICIs (Immune Checkpoint Inhibitors). In a clinical trial, co
Externí odkaz:
https://doaj.org/article/a9a844b15014448f8d6e92baf2f9b80d
Autor:
Lorraine Dalens, Julie Niogret, Corentin Richard, Sandy Chevrier, Pascal Foucher, Bruno Coudert, Aurélie Lagrange, Laure Favier, Virginie Westeel, Stefano Kim, Olivier Adotevi, Caroline Chapusot, Laurent Martin, Laurent Arnould, Courèche-Guillaume Kaderbhai, Romain Boidot
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-9 (2023)
Abstract Background Non-small cell lung cancer is a very poor prognosis disease. Molecular analyses have highlighted several genetic alterations which may be targeted by specific therapies. In clinical practice, progression-free survival on EGFR TKI
Externí odkaz:
https://doaj.org/article/fae01f6d6f6245acad2b87dbc4464121
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
A novel crosstalk between immunogenic and oncometabolic pathways triggered by T cell-released interferon-gamma (IFN-ɣ) has been recently identified. This IFN-ɣ-pyruvate kinase M2-β-catenin axis relies on fibroblast growth factor 2 (FGF2) signaling
Externí odkaz:
https://doaj.org/article/f6d020dd4ebb4375bf4315b5782ec187
Autor:
Lorraine Dalens, Julie Lecuelle, Laure Favier, Cléa Fraisse, Aurélie Lagrange, Courèche Kaderbhai, Romain Boidot, Sandy Chevrier, Hugo Mananet, Valentin Derangère, Caroline Truntzer, François Ghiringhelli
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 8, p 7592 (2023)
Immune checkpoint inhibitors (ICIs) have improved the care of patients in multiple cancer types. However, PD-L1 status, high Tumor Mutational Burden (TMB), and mismatch repair deficiency are the only validated biomarkers of efficacy for ICIs. These m
Externí odkaz:
https://doaj.org/article/f31cce86d33c478ba3751d2f5429b6dd
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionNon-small-cell lung cancer (NSCLC) is one of the main causes of death by cancer worldwide. With the rise of targeted therapies, the search for molecular abnormalities is becoming a crucial step in the management of lung cancer. Whole exom
Externí odkaz:
https://doaj.org/article/3ba6b19973334495ac6a2528a7d2f954
Autor:
François Ghiringhelli, Laure Favier, Cléa Fraisse, Valentin Derangère, Pascal Foucher, Lorraine Dalens, Caroline Truntzer, Vincent Goussot, Laurent Arnould, Sandy Chevrier, Juliette Albuisson, Aurélie Lagrange, Virginie Westeel, Romain Boidot, Julie Niogret, Courèche-Guillaume Kaderbhai, Ayoub Zouak, Bruno Coudert
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 161
Introduction Non-small-cell lung cancer (NSCLC) is one of the most common and deadly cancers. Several molecular drivers of oncogene addiction are now known to be strong predictive biomarkers for target therapies. Advances in large Next Generation Seq